Ticker Symbol: MNPR
Monopar Therapeutics Inc
$4.84 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001645469
Company Profile
Monopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin for the treatment of advanced soft tissue sarcoma; and a late-stagepreclinical antibody, MNPR-101, for advanced cancers and severe COVID-19.
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: 1000 Skokie Blvd Ste 350
Website: www.monopartx.com
CEO: N/A
Tags:
- Health Technology
- Biotechnology
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.55
Change:
-$0.04
(
-8.05%)
Days Range: $0.55 - $0.60
Beta: -0.10
52wk. High: $4.88
52wk. Low: $0.42
Ytd. Change -82.77%
50 Day Moving Average: $0.56
200 Day Moving Average: $0.82
Shares Outstanding: 14157941
Valuation
Market Cap: 779.8M
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A